The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part
elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin …

Recent genomic studies have identified novel recurrent somatic mutations in patients with
myeloid malignancies, including myeloproliferative neoplasms (MPNs), myelodysplastic …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Background Approximately 50 to 60% of patients with essential thrombocythemia or primary
myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to …

Under the auspices of an International Working Group, seven centers submitted diagnostic
and follow-up information on 1545 patients with World Health Organization-defined …

Patient outcome in primary myelofibrosis (PMF) is significantly influenced by karyotype. We
studied 879 PMF patients to determine the individual and combinatorial prognostic …

Calreticulin (CALR) mutations were recently described in JAK2 and MPL unmutated primary
myelofibrosis (PMF) and essential thrombocythemia. In the current study, we compared the …

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is
central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane …

In acute myeloid leukemia (AML), therapy resistance frequently occurs, leading to high
mortality among patients. However, the mechanisms that render leukemic cells drug …

The promise of targeting epigenetic abnormalities for cancer therapy has not been realized
for solid tumours, although increasing evidence is demonstrating its worth in haematological …